Evaluation of Vav3.1 as prognostic marker in endometrial cancer

Maximilian Boesch1,2,3,4 · Sieghart Sopper2,3,4 · Christian Marth5 · Heidi Fieg5 · Annemarie Wiedemair5 · Julia Rössler2 · Jiri Hatina6 · Dominik Wolf2,4,7 · Daniel Reimer4,5 · Alain G. Zeimet4,5

Received: 26 June 2018 / Accepted: 30 July 2018 / Published online: 6 August 2018
© The Author(s) 2018

Abstract

Purpose Vav3 is a guanine nucleotide exchange factor that regulates the activity of Rho/Rac family GTPases. In a study on ovarian cancer, we recently demonstrated pronounced prognostic and predictive value of Vav3.1, a specific truncation variant of the parental Vav3 gene. Here, we sought to investigate the role of Vav3.1 in the most prevalent gynecological tumor entity, endometrial cancer.

Methods Vav3.1 transcript levels were determined in a large cohort of endometrial cancer patients using variant-specific PCR (n = 239), and non-malignant endometrial tissue served as control (n = 26). Expression levels of Vav3.1 were stratified according to established clinicopathological characteristics and correlated to long-term patient survival (average follow-up of > 7.5 years). Type 1 and type 2 cancers were separately investigated.

Results While Vav3.1 was markedly overexpressed in endometrial cancer tissue, we could not detect associations with clinical parameters related to prognosis, such as FIGO stage and tumor grade. Kaplan–Meier estimators of different measures of survival failed to show prognostic significance of Vav3.1 in endometrial cancer. Lack of prognostic value was observed for both type 1 and type 2 cancers.

Conclusions Our study shows that Vav3.1 is not suited as a marker of cancer progression and/or treatment response in endometrial cancer. Feasibility and potential benefit of targeting Vav3.1 in endometrial cancer needs to be evaluated in future studies, proceeding from its clear, roughly ten-fold, induction in the malignant endometrium.

Keywords Vav3 · Guanine nucleotide exchange factor · Cancer · Endometrial cancer · Transcript variant · Protein isoform

Abbreviations

CSC Cancer stem cell
DFS Disease-free survival
EC Endometrial cancer
FIGO Fédération Internationale de Gynécologie et d’Obstétrique
GEF Guanine nucleotide exchange factor
OC Ovarian cancer
OS Overall survival
SP Side population

Maximilian Boesch and Sieghart Sopper contributed equally to this work.

Maximilian Boesch
Maximilian.Boesch@kssg.ch

Alain G. Zeimet
Alain.Zeimet@i-med.ac.at

1 Lungenzentrum, Kantonsspital St. Gallen, Rorschacherstrasse 95, 9007 St. Gallen, Switzerland
2 Internal Medicine V, Medical University of Innsbruck (MUI), 6020 Innsbruck, Austria
3 Tyrolean Cancer Research Institute (TKFI), 6020 Innsbruck, Austria
4 Oncotyrol, Center for Personalized Cancer Medicine GmbH, 6020 Innsbruck, Austria
5 Department of Gynecology and Obstetrics, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
6 Department of Biology and Biomedical Centre, Faculty of Medicine Pilsen, Charles University Prague, 30100 Pilsen, Czech Republic
7 Medical Clinic III, Oncology, Hematology and Rheumatology, University Clinic Bonn (UKB), 53127 Bonn, Germany
Introduction

Endometrial cancer (EC) is the most prevalent gynecological malignancy and has traditionally been classified into two major subtypes that differ in histological appearance and clinical behavior (Hecht and Mutter 2006). The much more common type 1 cancers (accounting for roughly 80% of cases), which show endometrioid morphology, are associated with unopposed estrogen exposure, and frequently arise from premalignant lesions (Hecht and Mutter 2006; Setiawan et al. 2013). In contrast, type 2 cancers are of non-endometrioid histology (usually serous or clear cell), depend on hormone stimulation to a lesser extent, typically arise in the aged atrophic endometrium, and are often poorly differentiated (Hecht and Mutter 2006; Setiawan et al. 2013). Accordingly, type 2 cancers generally exhibit a worse clinical outcome (Setiawan et al. 2013). Despite this, recent evidence suggests that the etiologies of type 1 and type 2 cancers are more similar to each other than previously thought, with many risk factors shared including nulliparity, early menarche, and obesity (Setiawan et al. 2013).

Compared with other gynecological tumors, EC shows a reasonably good prognosis even at more advanced stages. Nevertheless, novel markers of progression and treatment response are desirable to refine patient stratification for further improvement of survival rates. Moreover, certain patient subgroups exhibit poor outcome despite low-risk classification according to Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) staging, and filtering out these individuals is critical to consider additional therapeutic options early on hence preventing undertreatment of a whole patient subset (Zeimet et al. 2013).

Vav3 is a guanine nucleotide exchange factor (GEF) with specificity for Rho/Rac family GTPases (Movilla and Bustelo 1999), thus functioning as a regulator of cell motility, proliferation and differentiation (Hornstein et al. 2004). In addition, Vav3 is implicated in receptor-triggered angiogenesis (Hunter et al. 2006), and host deficiency in Vav2/Vav3 retards tumor growth based on impaired vascularization within the tumor bed (Brantley-Sieders et al. 2009). Vav3 has also been shown to mediate receptor tyrosine kinase signalling (Zeng et al. 2000) and to co-activate female (Lee et al. 2008) and male (Rao et al. 2012) hormone receptors. Importantly, Vav3 can induce cell transformation (Zeng et al. 2000) and targeted overexpression of Vav3 in prostatic epithelium induces tumor formation in mice (Liu et al. 2008). Consequently, Vav3 meets the key criterion of a bona fide oncogene. In the clinical setting, Vav3 is associated with cancer progression and recurrence (Lin et al. 2012) and furthermore mediates resistance to certain treatments, such as breast cancer endocrine therapy (Aguilar et al. 2014). Hence, Vav3 constitutes an established marker for cancer with prognostic and predictive significance, and accumulating evidence suggests a causal role in tumorigenesis that might be therapeutically exploitable.

Aside from Vav3, the mammalian Vav family comprises further two members, Vav1 and Vav2. Vav1 is specific for hematopoietic cells, whereas both Vav2 and Vav3 are more broadly expressed including expression in various epithelial and mesenchymal cell types (Bustelo 2000; Hornstein et al. 2004). More importantly, Vav3 can be subdivided into two main forms produced by alternative splicing, the full-length Vav3 alpha and the N-terminally truncated Vav3.1 (Boesch et al. 2018; Reimer et al. 2017; Trenkle et al. 2000). The latter form is devoid of several conserved domains including the region responsible for GEF activity, but has otherwise retained the potential for protein–protein interactions based on preserved SH2/SH3 motifs. The molecular properties of this isoform are virtually unknown, but dominant-negative effects on the full-length Vav3 alpha, or other modulating function within the Rho/Rac signalling circuit, are conceivable (Boesch et al. 2018).

In a study on ovarian cancer (OC), the most lethal gynecological tumor type (Cannistra 2004; Partridge and Barnes 1999), we recently established Vav3.1 as an important biomarker (Boesch et al. 2018; Reimer et al. 2017). High transcript levels of Vav3.1 were associated with poor overall survival (OS) and disease-free survival (DFS). Furthermore, abundant Vav3.1 message identified those patients that were refractory to platinum-based chemotherapy, the standard-of-care for OC patients. Of note, these analyses were inspired by an in-depth molecular profiling of the stem-like OC side population (SP) (Boesch et al. 2014) that showed upregulation of Vav3.1 especially in tumorigenic cells. Hence, the data suggested that CSC-specific/-enriched signatures bear prognostic and predictive significance in OC.

EC is stem cell-driven as well (Hubbard et al. 2009; Rutella et al. 2009), and evidence suggests that at least a sub-fraction of endometrial CSCs reside in the SP (Friel et al. 2008). However, EC is much less aggressive than OC and relapse rates are comparatively low (Kitchener et al. 2009; Notaro et al. 2016; Zeimet et al. 2013). This argues for significant differences in the underlying biology including (1) the degree of cellular heterogeneity and (2) the relative contribution of CSCs to disease progression. Hence, it remains unclear whether Vav3.1, as a factor potentially specific for CSCs, can serve as biomarker in EC. Here, we addressed this question in a monocentric retrospective study involving 239 patients.
Materials and methods

Patient samples

Tumor specimens were collected from EC patients undergoing primary surgery at the Department of Gynecology and Obstetrics at the Medical University of Innsbruck between the years 1989 and 2015 (n = 239). Endometrium samples from patients undergoing hysterectomy for reasons other than malignancy served as control (n = 26). Tissues were snap-frozen and pulverized directly after surgery and preserved at − 80 °C until RNA extraction. Patients have not been pre-selected or stratified according to clinicopathological risk factors, and there was no age-related cut-off.

Clinicopathological characteristics

Patients were monitored within the regular outpatient follow-up program of the Department of Gynecology and Obstetrics at the Medical University of Innsbruck, with an average observation time of 7.57 years (range 0.08–25.75). Tumors were staged according to the FIGO classification system (Werner et al. 2012), and histological subtype and grading were determined based on WHO criteria. The majority of patients were FIGO stage I (roughly two-thirds) and most of them received radiation therapy after surgical debulking (> 85%). In contrast, only around 20% of patients received adjuvant chemotherapy, with the most commonly used regimens being platinum- and taxane-based drugs, or combinations thereof. As expected, the vast majority of patients showed endometrioid histology (type 1 cancers; >80%), while the remaining fraction exhibited either type 2 disease (serous/clear cell) or a mixed Müllerian phenotype. Patient characteristics are summarized in Table 1. OS was defined as the time from surgery to the last follow-up or until death from any cause. DFS was defined as the time from surgery to relapse or until death from any cause. Follow-up information was available for all patients.

| Table 1  | Patient characteristics (n = 239) |
|----------|----------------------------------|
| Characteristics | Median (range) |
| Age (years) | 68.80 (36.52–92.92) |
| Overall survival (months) | 69.00 (1.00–309.00) |
| Disease-free survival (months) | 44.00 (0.00–280.00) |
| FIGO stagea | % |
| I | 155 | 64.85 |
| II | 15 | 6.28 |
| III | 59 | 24.69 |
| IV | 9 | 3.77 |
| Unknown | 1 | 0.42 |
| Histological subtype | |
| Endometrioid (type 1) | 201 | 84.10 |
| Serous/clear cell (type 2) | 23 | 9.62 |
| Mixed Müllerian | 15 | 6.28 |
| Histopathological grading | |
| 1 | 43 | 17.99 |
| 2 | 122 | 51.05 |
| 3 | 74 | 30.96 |
| Surgical resection/debulking | |
| Yes | 239 | 100.00 |
| No | 0 | 0.00 |
| Radiation therapy | |
| Yes | 206 | 86.19 |
| No | 33 | 13.81 |
| Chemotherapy | |
| Yes | 49 | 20.50 |
| No | 190 | 79.50 |

aFédération Internationale de Gynécologie et d’Obstétrique
RNA extraction and generation of cDNA

Total RNA was extracted from pulverized tissue using a commercial kit (RNAgents® Total RNA Isolation System; Promega, Fitchburg, WI), and samples were quality-controlled using gel analysis of ribosomal RNA (18S and 28S bands). Contaminating genomic DNA was eliminated through treatment with DNAsel (Roche, Basel, Switzerland), and cDNA was generated using random hexamer priming. Reaction conditions and cocktail composition are specified in a previous publication of ours (Reimer et al. 2007).

Primers and probes

The TaqMan® Gene Expression Assay Hs00610104_m1 (Applied Biosystems, Foster City, CA) was used to determine Vav2 expression levels (NM_001134398.1). To analyse TBP (housekeeper) and the Vav3 variants Vav3 alpha (full-length; NM_006113.4) and Vav3.1 (5′-truncated; NM_001079874.1), we designed specific primers and probes using Primer Express® software (Applied Biosystems) (Reimer et al. 2017). To avoid amplification of contaminating genomic DNA, primers were placed to span exons. Discrimination of Vav3 variants was accomplished positioning the forward primers between exons 18b and 19 (Vav3 alpha) and between exons 18a and 19 (Vav3.1). The reverse primer and probe were the same for both variants and were positioned within exon 20 and between exons 19 and 20, respectively. Primer and probe sequences for TBP, Vav3 alpha and Vav3.1 can be retrieved from (Reimer et al. 2017).

Quantitative real-time PCR

Amplification of cDNA templates was performed on an ABI PRISM 7900HT Sequence Detection System run by SDS 2.3 software (both from Applied Biosystems). Reactions were run in a volume of 25 µl and contained 12.5 µl TaqMan® Universal PCR Master Mix, 50 ng cDNA template, 900 nM of forward and reverse primer, respectively, and 250 nM of probe. The reaction conditions were a priming step of 50 °C for 2 min, a denaturing step of 95 °C for 10 min, and 45 cycles of 95 °C for 15 s and 65 °C for 1 min. All reactions were performed in triplicate with the mean value being used for subsequent calculation. Relative quantification of gene expression was done using the comparative C_T method and normalization to TBP. Amplification efficiencies were estimated based on external calibration with the ovarian cancer cell line HTB-77 (Reimer et al. 2017), and only experiments with an efficiency of >95% were included in the study.

Ethics statement

All patients gave written informed consent for use of their tissue in research. The study was approved by the local Institutional Ethical Review Board.

Statistical analysis

Differences between two groups were analysed using the Wilcoxon–Mann–Whitney test (e.g., cancer vs. healthy) or the Wilcoxon signed-rank test (Vav3/Vav3.1 matched-pairs). Differences between three or more groups were analysed using the Kruskal–Wallis test with Dunn’s correction for multiple comparisons (e.g., FIGO stage and tumor grade). Results are presented as individual data points with the median value indicated. Potential associations between transcript levels and patient survival were evaluated using Spearman correlation statistics. For survival analyses taking into account censoring, the Kaplan–Meier estimator was used along with log-rank statistical testing. GraphPad Prism version 7 (GraphPad Software, Inc., La Jolla, CA) was used for statistical testing. Tests were two-sided and a p value < 0.05 was considered significant.

Results

Upregulation of Vav3.1 in endometrial cancer

To discriminate between 5′-truncated Vav3.1 and Vav3 (covering both full-length Vav3 alpha and Vav3.1), we applied variant-specific PCR (to our knowledge, no Vav3.1-selective antibody exists). In addition, we determined the transcript levels of Vav2, another member of the Vav family showing non-hematopoietic expression. As compared to healthy controls, both Vav3 (Fig. 1a) and Vav3.1 (Fig. 1b) were highly upregulated in EC with an increase in median expression of more than ten-fold, respectively (p < 0.0001). In contrast, we found that Vav2, which was measured in a sub-fraction of patients (n = 90), was only marginally upregulated in the cancer specimens (1.12-fold increase, p = 0.0387) (Suppl. Figure 1). Of note, overexpression of Vav3/Vav3.1 was equally pronounced in type 1 (endometrioid) and type 2 (serous/clear cell) cancers (Fig. 1c, d), indicating a common mechanism of Vav3 activation among principal EC sub-entities. Moreover, a paired analysis revealed great concordance between Vav3 and Vav3.1 expression in the individual patient, with Vav3 yielding only a slightly higher signal (median value 2.47 vs. 2.20, p < 0.0001) (Suppl. Figure 2). Together, these data provide evidence for significant upregulation of Vav3 and Vav3.1 in EC. The concordant expression pattern of Vav3 and Vav3.1 in individual patients suggests that most of the intratumoral Vav3 message originates from...
truncation variant Vav3.1, with only a minor contribution from full-length Vav3 alpha.

**Independence from clinicopathological characteristics**

Overall, we observed a high variation in Vav3/Vav3.1 transcript levels in our patient cohort (Table 1), which ranged from 0.01 to 10, thus spanning about three log decades (Fig. 1a–d and Suppl. Figure 2). We thus sought to test a possible association with established clinicopathological parameters, to see whether Vav3/Vav3.1 expression levels can discriminate between discrete patient subgroups. However, expression of Vav3/Vav3.1 did not change with FIGO stage (Fig. 2a, b), and there was no appreciable association with tumor grade (Fig. 2c, d). The same results were obtained in a separate analysis of type 1 and type 2 cancers (data not shown). Finally, Vav3/Vav3.1 levels also did not discriminate the subgroup of distantly metastasized patients (Fig. 2e, f), thus questioning a pronounced role in dissemination and systemic disease. Collectively, these data suggest that upregulation of Vav3/Vav3.1 expression in EC tissue occurs independently from various clinicopathological features that bear prognostic and/or predictive significance.

**Vav3.1 levels fail to predict survival of endometrial cancer patients**

Lack of association with clinicopathological characteristics does not rule out independent prognostic relevance of a molecular marker. We, therefore, assessed whether Vav3/Vav3.1 transcript levels correlated with patient survival (OS and DFS). In an uncensored analysis, we could not discover significance of correlation between Vav3/Vav3.1 expression and patient survival, neither in pooled analyses (Fig. 3a–d) nor upon separation of type 1 and type 2 cancers (data not shown). Accordingly, Kaplan–Meier estimators taking into account censoring failed to demonstrate prognostic significance of Vav3/Vav3.1 expression after sectioning according to 50th percentile statistics (Fig. 4a–d). We obtained the same results for other percentiles as well (data not shown). These data
consistent show that neither Vav3 nor Vav3.1 is significantly associated with patient survival, indicating that neither transcript is suitable as a prognostic tool to predict EC patient outcome.

**Discussion**

EC is the most common gynecological cancer (Hecht and Mutter 2006) and exhibits a fairly good prognosis even at
more advanced stages. Notwithstanding, low-risk classification based on FIGO I staging does not reliably identify patients with excellent prognosis who are indeed protected from recurrence (Zeimet et al. 2013). Thus, certain patient subgroups are at risk of undertreatment and novel prognostic markers are desirable to refine outcome prediction for a better initial stratification.

In a study on OC, we recently established prognostic significance of Vav3.1 in all major clinical subtypes (Boesch et al. 2018; Reimer et al. 2017). In addition, we found that high levels of Vav3.1 filtered out those patients that never responded to platinum-based treatment (i.e., genuine platinum refractoriness). Importantly, this retrospective study followed an exploratory analysis that linked Vav3.1 expression to phenotypic and functional CSC properties (overexpression in OC SP cells). Here, we tried to translate these findings to a gynecological tumor entity characterized by a much less aggressive clinical course.

The results from this large monocentric study demonstrate that both Vav3 and its transcript variant Vav3.1 are highly upregulated in EC. In addition, we discovered great concordance of Vav3 (covering both full-length Vav3 alpha and 5'-truncated Vav3.1) and Vav3.1 transcript levels in individual patients, suggesting that overexpression of Vav3 in tumor tissue is mainly due to Vav3.1, similarly as in OC (Reimer et al. 2017). Nevertheless, thorough investigations failed to demonstrate significant association with clinicopathological parameters, and the transcripts were also not able to predict EC patient survival. We, therefore, conclude that neither Vav3 nor Vav3.1 bears prognostic significance in EC. Other biomarkers, such as the recently discovered L1CAM (CD171) (Zeimet et al. 2013), therefore, remain unrivaled in prognosticating disease progression and recurrence in EC.

EC is associated with several recurrent mutations and other aberrations; however, the chronology of these events as well as the eventual genetic constellation underlies significant inter-patient variation (Hecht and Mutter 2006). Type 1 cancers often show defects in mismatch repair genes as well as specific mutations in *PTEN*, *K-ras* and *β-catennin* (Hecht and Mutter 2006; Kitchener et al. 2009). On the other hand, the much less common type 2 cancers frequently exhibit aneuploidy genotypes as well as mutations in the core tumor suppressor *TP53* (Hecht and Mutter 2006; Kitchener et al.

---

**Fig. 3** No correlation of Vav3/Vav3.1 expression with endometrial cancer survival. Vav3/Vav3.1 transcript levels were analysed for potential correlation with overall survival (**A, B**) and disease-free survival (**C, D**) using Spearman statistics. n.s. (*p* > 0.05)
2009). Of note, the key role of PTEN in endometrial cancer suppression has been demonstrated and confirmed in pten+/− mice, which develop endometrial hyperplasia and endometrial cancer with 100 and 20% penetrance, respectively (Stambolic et al. 2000). It is conceivable that in EC, Vav3.1 overexpression is regulated independently from these ‘driver’ mutations such that the level of expression does not correlate with clinicopathological features or survival. Alternatively, the detected Vav3.1 message might originate from non-malignant ‘bystander’ cells, whose presence may not be linked to tumor progression (e.g., particular populations of tumor-infiltrating immune cells, or stromal/endothelial cells).

Like most other organs of the adult, the endometrium represents a hierarchically organized tissue sustained and replenished by dedicated populations of stem cells (Verdi et al. 2014). In the endometrium, this stem cell pool appears to comprise cells of different lineages including epithelium, mesenchyme and endothelium, which is a quite special situation (Chan et al. 2004; Gargett and Masuda 2010).
endometrium also shows expression of embryonic stem cell antigens (Matthai et al. 2006) and interestingly, one of the lead candidate markers for the definition of endometrial stem cells is the SP phenotype (Friel et al. 2008; Masuda et al. 2015). There is evidence that the transformed endometrium harbors stem cell populations as well, which fuel malignant progression and escape the cytotoxic effects of chemotherapy; accordingly, clinical translation and therapeutic targeting of this cell pool is envisaged (Carvalho et al. 2018; Reimer et al. 2017). It might be that Vav3.1 is less specific for CSCs in EC and that accordingly, more differentiated tumor cells account for most of the detected signal. Alternatively, the relative abundance of CSCs might be lower in EC such that fewer cells contribute Vav3.1 message and CSC specificity of the signature is lost. Indeed, we found that the median expression of Vav3.1 was higher in OC (4.58) (Reimer et al. 2017) than in EC (2.2).

In support of this hypothesis, OC is a particularly aggressive tumor type showing high rates of recurrence and frequent acquisition of drug resistance (Zeimet et al. 2012), both of which are associated with CSCs and tumoral stemness (Boesch et al. 2014, 2015, 2016a, b). In contrast, the relatively slow progression kinetics and favorable outcome of EC (Kitchener et al. 2009; Notaro et al. 2016; Zeimet et al. 2013) portend that this tumor entity may be less driven by CSCs. Assuming CSC specificity of the Vav3.1 transcript, this could at least partially explain their lack of association with patient survival and clinicianopathological features in EC.

The fact that Vav3.1 cannot be harnessed for prognostic inferences in EC does not rule out the possibility that its targeting can confer therapeutic benefit. We thus suggest that in the effort of developing Vav3.1-targeting drugs, EC should not be forgotten as a potential indication, even though other tumor types will definitely be at the forefront of these investigations. In the meantime, it should be established on the level of genetic specificity whether Vav3.1 expression affects fundamental stem cell properties in EC, such as clonogenicity, tumorigenicity, and chemo-sensitivity.

Collectively, we here show that Vav3.1 does not serve as biomarker for EC progression, despite significant overexpression in tumor tissue. This might be a direct consequence of the rather lowly aggressive clinical behaviour of this tumor type which is indicative of an exhausted tumoral stemness potential or generally a small contribution from CSCs. Further research is required to see whether Vav3.1 targeting bears therapeutic potential in EC.

Acknowledgements Open access funding provided by Austrian Science Fund (FWF). This work was supported by the Verein zur Krebsforschung in der Frauenheilkunde and Oncotyrol—Center for Personalized Cancer Medicine GmbH. The Competence Center Oncotyrol is funded within the scope of the COMET—Competence Centers for Excellent Technologies through BMVIT, BMWFW, through the province of Salzburg and the Tiroler Zukunftsstiftung/Standortagentur Tirol. The COMET Program is conducted by the Austrian Research Promotion Agency (FGF). MB is supported by an Erwin Schrödinger Fellowship of the Austrian Science Fund FWF (grant number J-3807).

Author contributions Conception and design: MB, SS, DR, AGZ. Collection and/or assembly of data: MB, SS, HF, AW, JR, DR, AGZ. Data analysis and interpretation: MB, SS, CM, HF, JH, DW, DR, AGZ. Designed and generated the figures: MB. Manuscript writing: MB, SS, DR, AGZ. Approved the paper for submission and publication: MB, SS, CM, HF, AW, JR, JH, DW, DR, AGZ (all authors).

Compliance with ethical standards

Conflict of interest MB, SS, DW, DR and AGZ are the inventors of a Vav3-related patent application held by Oncotyrol—Center for Personalized Cancer Medicine GmbH (WO2016066604A1). The authors have no other conflicts of interest to declare. No medical writer (or other non-author) was involved in the preparation of the manuscript.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Aguilar H et al (2014) VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Res: BCR 16:R53. doi: 10.1186/bcr3664
Boesch M et al (2014) The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem. Cell Char Oncotarget 5:7027–7039
Boesch M, Zeimet AG, Rumpold H, Gastl G, Sopper S, Wolf D (2015) Drug transporter-mediated protection of cancer stem cells from ionophore antibiotics. Stem Cells Transl Med. https://doi.org/10.5966/sctm.2015-0054
Boesch M, Sopper S, Wolf D (2016a) Ionophore antibiotics as cancer stem cell-selective drugs: open questions. Oncologist. https://doi.org/10.1634/theoncologist.2016-0159
Boesch M, Sopper S, Zeimet AG, Reimer D, Gastl G, Wolf D, Wolf D (2016b) Heterogeneity of cancer stem cells: rationale for targeting the stem cell niche biochimica. Et Biophysica Acta 1866:276–289. https://doi.org/10.1016/j.cba.2016.10.003
Boesch M, Reimer D, Sopper S, Wolf D, Zeimet AG (2018) Iso-form matters: differential implication of Vav3 variants in ovarian cancer oncologist. https://doi.org/10.1634/theoncologist.2017-0683
Brantley-Sieders DM, Zhuang G, Vaugh D, Freeman T, Hwang Y, Hicks D, Chen J (2009) Host deficiency in Vav2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and
angiogenesis in vivo molecular cancer research. MCR 7:615–623. https://doi.org/10.1158/1541-7786.MCR-08-0401

Bustelo XR (2000) Regulatory and signaling properties of the Vav family. Mol Cell Biol 20:1461–1477

Bustelo XR, Vinuela C, de la Llave A, Gonzalez-Scarano F (2000) Tumour promoting properties of Vav-3, a new member of the Vav family of oncogenes. J Cell Sci 113:3453–3461

Chan RW, Schwab KE, Gargett CE (2004) Clonogenicity of human endometrial carcinoma cells. Mol Hum Reprod 10:547–557. https://doi.org/10.1093/molehr/gag061

Gotte M et al (2011) The adult stem cell marker Musashi-1 modulates endometrial carcinoma cell cycle progression and apoptosis via Notch-1 and p21WAF1/CIP1. Int J Cancer 129:2042–2049. https://doi.org/10.1002/ijc.25856

Hecht JL, Mutter GL (2006) Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 24:4783–4791. https://doi.org/10.1200/JCO.2006.06.7173

Hornstein I, Alcover A, Katzav S (2004) Vav proteins, masters of the world of cytoskeleton organization. Cell Signal 16:1–11

Hubbard SA, Friel AM, Kumar B, Zhang L, Rueda BR, Gargett CE (2009) Evidence for cancer stem cells in human endometrial carcinoma. Cancer Res 69:8241–8248. https://doi.org/10.1158/0008-5472.CAN-08-4808

Hunter SG, Zhuang G, Brantley-Sieders D, Swat W, Cowan CW, Chen J (2006) Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis. Mol Cell Biol 26:4830–4842. https://doi.org/10.1128/MCB.02215-05

Kitchener HC, Trimble EL, Endometrial Cancer Working Group of the Gynecologic Cancer I (2009) Endometrial cancer state of the science meeting. Int J Gynecol Cancer 19:134–140. https://doi.org/10.1111/j.1525-1965.2008.8876.x

Kusunoki S et al (2013) The inhibitory effect of salinomycin on the proliferation, migration and invasion of human endometrial cancer stem-like cells. Gynecol Oncol 129:598–605. https://doi.org/10.1016/j.ygyno.2013.03.005

Lee K, Liu Y, Mo JQ, Zhang J, Dong Z, Lu S (2008) Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer. BMC Cancer 8:158. https://doi.org/10.1186/1471-2407-8-158

Lin KT, Gong J, Li CF, Jang TH, Chen WL, Chen HJ, Wang LH (2012) Vav3-rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence. Cancer Res 72:3000–3009. https://doi.org/10.1158/0008-5472.CAN-11-2502

Liu Y et al (2008) Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer. Cancer Res 68:6396–6406. https://doi.org/10.1158/0008-5472.CAN-08-0645

Masuda H, Maruyama T, Gargett CE, Miyazaki K, Matsuzaki Y, Okano H, Tanaka M (2015) Endometrial side population cells: potential adult stem/progenitor cells in endometrium. Biol Reprod 93:84. https://doi.org/10.1095/biolreprod.115.131490

Matthai C et al (2006) Oct-4 expression in human endometrium. Mol Hum Reprod 12:7–10. https://doi.org/10.1093/molehr/gah254

Movilla N, Bustelo XR (1999) Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins. Mol Cell Biol 19:7870–7885

Notaro S et al (2016) Evaluating L1CAM expression in human endometrial cancer using qRT-PCR. Oncotarget 7:40221–40232. https://doi.org/10.18632/oncotarget.9574

Partridge EE, Barnes MN (1999) Epithelial ovarian cancer: prevention, diagnosis, and treatment CA: a cancer. J Clin 49:297–320

Rao S, Lyons LS, Fahrenholtz CD, Wu F, Farooq A, Balkan W, Burnstein KL (2012) A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer. Oncogene 31:716–727. https://doi.org/10.1038/onc.2011.273

Reimer D et al (2007) Clinical relevance of E2F family members in ovarian cancer—an evaluation in a training set of 77 patients. Clin Cancer Res 13:144–151. https://doi.org/10.1158/1078-0432.CCR-06-0780

Reimer D et al (2017) Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response. Int J Cancer. https://doi.org/10.1002/ijc.31186

Rutella S et al (2009) Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res 15:4299–4311. https://doi.org/10.1158/1078-0432.CCR-08-1883

Setiawan VW et al (2013) Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 31:2607–2618. https://doi.org/10.1200/JCO.2012.48.2596

Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW (2000) High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res 60:3605–3611

Trenkle T, McClelland M, Adlkofer K, Welsh J (2000) Major transcript variants of VAV3, a new member of the VAV family of guanine nucleotide exchange factors. Gene 245:139–149

van der Zee M et al (2015) IL6/JAK1/STAT3 signaling blockade in endometrial cancer affects the ABLHhii/CD126 + stem-like component and reduces tumor. Burden Cancer Res 75:3608–3622. https://doi.org/10.1186/1754-1471-75-1

Verdi J, Tan A, Shohae-Hassani A, Seifalian AM (2014) Endometrial stem cells in regenerative medicine. J Biol Eng 8:20. https://doi.org/10.1186/1754-1611-8-20

Werner HM et al (2012) Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification. Gynecol Oncol 125:103–108. https://doi.org/10.1016/j.ygyno.2011.11.008

Zeimet AG et al (2013) Type I endometrial cancer affects the ALDHhi/CD126 + stem-like compartment and reduces tumor. Burden Cancer Res 75:3608–3622. https://doi.org/10.1186/1754-1471-75-1

Zeimet AG et al (2013) L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst 105:1142–1150. https://doi.org/10.1093/jnci/djt144

Zeng L et al (2000) Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. Mol Cell Biol 20:9212–9224